Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma

Fig. 2

Survival Outcomes in RRMM Patients Treated with BCMA CAR-T Therapy. (A, B, C) Kaplan‒Meier survival curves illustrating the DOR, PFS, and OS for all 56 patients. (D) Accumulated best response rates after CAR-T-cell therapy. The red line indicates the progressive increase in the rates of CR or sCR over time. CR, complete response; DOR, duration of response; PFS, progression-free survival; PR, partial response; OS, overall survival; sCR, stringent complete response; VGPR, very good partial response

Back to article page